Cargando…

Clinical Pharmacokinetics and Pharmacodynamics of Dalcetrapib

The cholesterol ester transfer protein (CETP) inhibitor dalcetrapib has been under evaluation for its potential to prevent cardiovascular (CV) events for almost two decades. The current clinical development program, representing new advances in precision medicine and focused on a genetically defined...

Descripción completa

Detalles Bibliográficos
Autores principales:	Black, Donald M., Bentley, Darren, Chapel, Sunny, Lee, Jongtae, Briggs, Emily, Heinonen, Therese
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182459/ https://www.ncbi.nlm.nih.gov/pubmed/29730761 http://dx.doi.org/10.1007/s40262-018-0656-3

Ejemplares similares

Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial( )
por: Tardif, Jean Claude, et al.
Publicado: (2022)

Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib
por: Goldberg, Alyse S, et al.
Publicado: (2012)

Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease
por: Schwartz, Gregory G., et al.
Publicado: (2020)

Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes
por: Tardif, Jean-Claude, et al.
Publicado: (2016)

Population pharmacokinetic and pharmacokinetic-pharmacodynamic modeling of bempedoic acid and low-density lipoprotein cholesterol in healthy subjects and patients with dyslipidemia
por: Jadhav, Satyawan B., et al.
Publicado: (2023)

Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab
por: Tang, Weifeng, et al.
Publicado: (2023)

Clinical Pharmacokinetics and Pharmacodynamics of Propofol
por: Sahinovic, Marko M., et al.
Publicado: (2018)

Dalcetrapib and anacetrapib differently impact HDL structure and function in rabbits and monkeys
por: Brodeur, Mathieu R., et al.
Publicado: (2017)

Dalcetrapib and anacetrapib increase apolipoprotein E-containing HDL in rabbits and humans
por: Brodeur, Mathieu R., et al.
Publicado: (2022)

Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine
por: Weerink, Maud A. S., et al.
Publicado: (2017)

Clinical Pharmacokinetics and Pharmacodynamics of Micafungin
por: Wasmann, Roeland E., et al.
Publicado: (2017)

Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide
por: Chen, Nianhang, et al.
Publicado: (2016)

Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib
por: Wind, Sven, et al.
Publicado: (2019)

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib
por: Wind, Sven, et al.
Publicado: (2016)

Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol
por: Bilal, Muhammad, et al.
Publicado: (2021)

Clinical Pharmacokinetics and Pharmacodynamics of Roxadustat
por: Czock, David, et al.
Publicado: (2021)

Clinical Pharmacokinetics and Pharmacodynamics of Desmoteplase
por: Piechowski-Jozwiak, Bartlomiej, et al.
Publicado: (2021)

Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib
por: Liao, Mingxiang, et al.
Publicado: (2022)

Clinical Pharmacokinetics and Pharmacodynamics of Voclosporin
por: Abdel-Kahaar, Emaad, et al.
Publicado: (2023)

Pharmacokinetic‐pharmacodynamic model of urinary δ‐aminolevulinic acid reduction after givosiran treatment in patients with acute hepatic porphyria
por: Lee, Jongtae, et al.
Publicado: (2023)

Inhibition of the 3CL Protease and SARS-CoV-2 Replication by Dalcetrapib
por: Niesor, Eric J, et al.
Publicado: (2021)

Saturable human neopterin response to interferon-α assessed by a pharmacokinetic-pharmacodynamic model
por: Jeon, Sangil, et al.
Publicado: (2013)

Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban
por: Mueck, Wolfgang, et al.
Publicado: (2013)

Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat
por: Frey, Reiner, et al.
Publicado: (2017)

Clinical Pharmacokinetics and Pharmacodynamics of CSL112
por: Ortega-Paz, Luis, et al.
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
por: McCarthy, Matthew William
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Tedizolid
por: Iqbal, Khalid, et al.
Publicado: (2022)

Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors
por: Centanni, Maddalena, et al.
Publicado: (2019)

Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review
por: Byon, Wonkyung, et al.
Publicado: (2019)

Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients
por: Pang, Yinuo, et al.
Publicado: (2019)

Ticagrelor: Pharmacokinetics, Pharmacodynamics, Clinical Efficacy, and Safety
por: Dobesh, Paul P, et al.
Publicado: (2014)

The Pharmacokinetics and Pharmacodynamics of Iron Preparations
por: Geisser, Peter, et al.
Publicado: (2011)

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing
por: Verheijen, Remy B., et al.
Publicado: (2017)

Arylcyclohexylamine Derivatives: Pharmacokinetic, Pharmacodynamic, Clinical and Forensic Aspects
por: Pelletier, Romain, et al.
Publicado: (2022)

Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial
por: Stein, Evan A., et al.
Publicado: (2010)

Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides
por: al Jalali, Valentin, et al.
Publicado: (2018)

Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis
por: Berends, Sophie E., et al.
Publicado: (2018)

Clinical Pharmacokinetics and Pharmacodynamics of the Endothelin Receptor Antagonist Macitentan
por: Sidharta, P. N., et al.
Publicado: (2015)

A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab
por: Rosario, Maria, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ca8u2id3hiuc1e68o5vf2ske07